Bone marrow glycophorin-positive erythroid cells of myelodysplastic patients responding to high-dose rHuEPO therapy have a different gene expression pattern from those of nonresponders

American Journal of Hematology

Volumn 83, Issue 7, 2008, Pages 531-539

  Cortelezzi, Agostino ^a,b   Colombo, Gualtiero ^a   Pellegrini, Caterina ^c   Silvestris, Ilaria ^a,b   Mazzeo, Lorenza Moronetti ^a   Bosari, Silvano ^b,c   Deliliers, Giorgio Lambertenghi ^a,b   Fracchiolla, Nicola Stefano ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Pathology Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLINE; ERYTHROPOIETIN; GLYCOPHORIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SEPARATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA REPAIR; DRUG DOSE REDUCTION; ENZYME ACTIVITY; ERYTHROID CELL; FEMALE; GENE EXPRESSION PROFILING; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMAGNETIC SEPARATION; MALE; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; VALIDATION PROCESS; VIRUS ONCOGENE;

AGED; AGED, 80 AND OVER; BONE MARROW CELLS; CLUSTER ANALYSIS; DOWN-REGULATION; ERYTHROID CELLS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLYCOPHORIN; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; UP-REGULATION;

EID: 45749089037     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21178     Document Type: Article

References (82)

1. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995;83:59-67.
2. Lin CS, Lim SK, D'Agati V, Costantini F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev 1996;10:154-164.
3. Roeder I, de Haan G, Engel C, et al. Interactions of erythropoietin, granulocyte colony-stimulating factor, stem cell factor, and interleukin-11 on murine hematopoiesis during simultaneous administration. Blood 1998;91:3222-3229.
4. de Haan G, Dontje B, Nijhof W. Concepts of hemopoietic cell amplification. Synergy, redundancy and pleiotropy of cytokines affecting the regulation of erythropoiesis. Leuk Lymphoma 1996;5-6:385-394.
5. Flores-Guzman P, Gutierrez-Rodriguez M, Mayani H. In vitro proliferation, expansion, and differentiation of a CD34+ cell-enriched hematopoietic cell population from human umbilical cord blood in response to recombinant cytokines. Arch Med Res 2002;33:107-114.
6. Dybedal I, Larsen S, Jacobsen SE. IL-12 directly enhances in vitro murine erythropoiesis in combination with IL-4 and stem cell factor. J Immunol 1995;15:154:4950-4955.
7. - erythroid progenitors in normal human bone marrow in the absence of serum. Exp Hematol 1992;20: 418-424.
8. Johnson CS, Keckler DJ, Topper MI, et al. In vivo hematopoietic effects of recombinant interleukin-1 alpha in mice: Stimulation of granulocytic, monocytic, megakaryocyte, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood 1989;15:73:678-683.
9. Jegalian AG, Acurio A, Dranoff G, Wu H. Erythropoietin receptor haploinsufficiency and in vivo interplay with granulocyte-macrophage colony-stimulating factor and interleukin 3. Blood 2002;99:2603-2605.
10. Sawyer ST, Penta K. Erythropoietin cell biology. Hematol Oncol Clin North Am 1994;8:895-911.
11. D'Andrea AD, Zon LI. Erythropoietin receptor: Colon subunit structure and activation. J Clin Invest 1990;86:681-687.
12. Sawada K, Krantz SB, Dai C-H, et al. Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptor. J Cell Physiol 1990;142:219-230.
13. Wickrema A, Krantz SB, Winkelmann JC, Bondurant MC. Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells. Blood 1992;80:1940-1949.
14. Kubatzky KK, Ruan W, Gurezka R, et al. Self-assembly of the trans-membrane domain promotes signal transduction through the erythropoietin receptor. Curr Biol 2001;11:110-115.
15. Constantinescu JN, Keren T, Socolovsky M. Ligand-independent oligomerizatin of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci USA 2001;98:4379-4384.
16. Pallard C, Fabrice G, Martine C, et al. Interleukin-3, erythropoietin, and prolactin activate a STAT5 line factor in lymphoid cells. J Biol Chem 1995;270: 15942-15945.
17. Wakao H, Harada N, Kitamura T, et al. Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways. EMBO J 1995;14:2527-2535.
18. Penta K, Sawyer ST. Erythropoietin induces tyrosins phosphorylation, nuclear translocation, and DNA binding of STAT1 and STAT5 in erythroid cells. J Biol Chem 1995;270:31282-31287.
19. Watowich SS, Mikami A, Busche RA, et al. Erythropoietin receptors that signal through Stat5 or Stat3 support fetal liver and adult erythropoiesis: lack of specificity of STAT signals during red blood cell development. J Interferon Cytokine Res 2000;20:1065-1070.
20. Ihle JN. Cytokine receptor signaling. Nature 1995;377:591-594.
21. Damen JE, Wakao H, Miyajima A, et al. Tyrosine 343 in the erythropoietin-receptor positively regulates erythropoietin-induced cell proliferation and STAT5 activation. EMBO J 1995;14:5557-5568.
22. Witthuhn B, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following Epo stimulation. Cell 1996;74:227-236.
23. Carrol MP, Spivak JL, McMahon M, et al. Erythropoietin induces Raf-1 activation and Raf-1 is required for erythropoietin-mediated proliferation. J Biol Chem 1991;266:14964-14969.
24. Gobert S, Duprez V, Lacombe C, et al. Erythropoietin activates three forms of MAP kinase in UT7 erythroleukemia cells. Eur J Biochem 1995;234:75-83.
25. Miura Y, Muira O, Ihle JN, Aoki N. Activation of the mitogen activated protein kinase pathway by the erythropoietin receptor. J Biol Chem 1994;269:29962-29969.
26. Shan R, Price JO, Guarde WA, et al. Distinct roles of JNKs/p38 MAP kinase and ERKs in apoptosis and survival of HCP-57 cells induced by withdrawal or addition of erythropoietin. Blood 1999;94:4067-4076.
27. Jacobs-Helber SM, Ryan SM, Sawyer JJ. JNK p38 are activated by erythropoietin EPO but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD 57 cells. Blood 2000;96:933-940.
28. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
29. WHO Classification Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2001.
30. Heaney ML, Golds DW. Myelodysplasia. NEJM 1999;340:1649-1654.
31. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 1998;83:358-368.
32. Mufti GJ. Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Baillieres Best Pract Res Clin Haematol 2004;17:543-557.
33. Morrow GR, Andrews PL, Hickok JT, et al. Fatigua associated with cancer and its treatment. Support Care Cancer 2002;10:389-398.
34. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998;25: (Suppl)17:43-46.
35. Alessandrino EP, Amadori S, Barosi G, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002;87: 1286-1306.
36. Cazzola M, Anderson JE, Ganser A, Hellstrom-Lindberg E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica 1998;83:910-935.
37. Cazzola M, Ponchio L, Beguin Y, et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 1992;79:29-37.
38. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies. Br J Haematol 2005;89:67-71.
39. Spiriti MA, Latagliata R, Niscola P, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Annals Hematol 2005;84:167-176.
40. Rigolin GM, Porta MD, Bigoni R, et al. rHuEpo adm nistration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization or May-Grunwald-Giemsa-stained bone marrow samples. Br J Haematol 2002;119:652-659.
41. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomized double blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 1998;103:1070-1074.
42. Terpos E, Mougiou A, Kouraklis A, et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 2002;118:174-180.
43. Demetri GD, Kris M, Wade J, et al, for the Procrit Study Group. Quality of life benefit in chemotherapy patients treated with epoetin alpha is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-3425.
44. Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial. Blood 2004;104:321-327.
45. Mantovani L, Lentini G, Hentschel B, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 2000;109:367-375.
46. Qian J, Chen Z, Wang W, et al. Gene expression profiling of the bone marrow mononuclear cells from patients with myelodysplastic syndrome. Oncol Rep 2005;14:1189-1197.
47. Ueda M, Ota J, Yamashita Y, Choi YL, et al. DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome. Br J Haematol 2003;123:288-296.
48. Coutts M, Cui K, Davis KL, et al. Regulated expression and functional role of the transcription factor CHOP GADD153 in erythroid growth and differentiation. Blood 1999;93:3369-3378.
49. Bessa M, Joaquin M, Tavner F, et al. Regulation of the cell cycle by B-Myb. Blood Cells Mol Dis 2001;27:416-421.
50. Blais JD, Filipenko V, Bi M, et al. Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell Biol 2004;24:7469-7482.
51. Ameri K, Lewis CE, Raida M, et al. Anoxic induction of ATF-4 through HIF-1-independent pathways of protein stabilization in human cancer cells. Blood 2004;103:1876-1882.
52. Hirai H, Roussel MF, Kato J-Y, et al. Novel INK4 proteins, p19 and p18, are specific inhibitors of cyclin D-dependent kinases CDK4 and CDK6. Molec Cell Biol 1995;15:2672-2681.
53. Zhan Q. Gadd45a, a p53- and BRCA1-regulated stress protein, in cellular response to DNA damage. Mutat Res 2005;569:133-143.
54. Majka J, Burgers PM. The PCNA-RFC families of DNA clamps and clamp loaders. Prog Nucleic Acid Res Mol Biol 2004;78:227-260.
55. Aroya SB, Kupiec M. The EIg1 replication factor C-like complex: A novel guardian of genome stability. DNA Repair 2005;4:409-417.
56. Mossi R, Hübscher U. Clamping down on clamps and clamp loaders - The eukaryotic replication factor C. Eur J Biochem 1998;254:209-216.
57. Noskov VN, Araki H, Sugino A. The RFC2 gene, encoding the third-largest subunit of the replication factor C complex, is required for an S-phase checkpoint in Saccharomyces cerevisiae. Mol Cell Biol 1998;18:4914-4923.
58. Fracchiolla NS, Bamonti Catena F, Novembrino C, et al. Possible association between reactive oxygen metabolites and karyotypic abnormalities in myelodysplastic syndromes. Haematologica 2003;88:594-597.
59. Peddie CM, Wolf CR, McLellan LI, et al. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol 1997;99:625-631.
60. Kim MR, Chang HS, Kim BH, et al. Involvements of mitochondrial thioredoxin reductase. TrxR2 in cell proliferation. Biochem Biophys Res Commun 2003;304:119-124.
61. Neumann CA, Krause DS, Carman CV, et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defense and tumour suppression. Nature 2003;424:561-565.
62. Lee KA, Kim SH, Woo HY, et al. Increased frequencies of glutathione S-transferase. GSTM1 and GSTT1 gene deletions in Korean patients with acquired aplastic anemia. Blood 2001;98:3483-3485.
63. Zhang J, Lodish HF. Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic Ç-ras expression in primary erythroid progenitors. Blood 2004;104:1679-1687.
64. Fuller JF, McAdara J, Yaron Y, et al. Characterization of HOX gene expression during myelopoiesis: Role of HOX A5 in lineage commitment and maturation. Blood 1999;93:3391-3400.
65. Qiu Q, Yang M, Tsang BK, Gruslin A. EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways. Reproduction 2004;128:355-363.
66. Qiu Q, Yang M, Tsang BK, Gruslin A. EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways. Reproduction 2004;128:355-363.
67. Woo CH, Lim JH, Kim JH. Lipopolysaccharide induces matrix metalloproteinase-9 expression via a mitochondrial reactive oxygen species-p38 kinase-activator protein-1 pathway in Raw 264.7 cells. J Immunol 2004;173:6973-6980.
68. Suarez-Cuervo C, Merrell MA, Watson L, et al. Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clin Exp Metastasis 2004;21:525-533.
69. Tong L, Smyth D, Kerr C, et al. Mitogen-activated protein kinases Erk1/2 and p38 are required for maximal regulation of TIMP-1 by oncostatin M in murine fibroblasts. Cell Signal 2004;16:1123-1132.
70. Lee SJ, Yoo HJ, Bae YS, et al. TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src. Biochem Biophys Res Commun 2003;312:1196-1201.
71. Munshi HG, Wu YI, Mukhopadhyay S, et al. Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-β1-induced pericellular collagenolysis. J Biol Chem 2004;279:39042-39050.
72. Akahane T, Akahane M, Shah A, Thorgeirsson UP. TIMP-1 stimulates proliferation of human aortic smooth muscle cells and Ras effector pathways. Biochem Biophys Res Commun 2004;324:440-445.
73. Sgarra R, Rustighi A, Tessari MA, et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett 2004; 574:1-8.
74. Masuoka HC, Townes TM. Targeted disruption of the activating transcription factor 4 gene results in severe fetal anemia in mice. Blood 2002;99:736-745.
75. Averous J, Bruhat A, Jousse C, et al. Induction of CHOP expression by amino acid limitation requires both ATF4 expression and ATF2 phosphorylation. J Biol Chem 2004;279:5288-5297.
76. Lasorella A, Uo T, Iavarone A. Id proteins at the cross-road of development and cancer. Oncogene 2001;20:8326-8333.
77. Tsiara SN, Chaidos A, Gouva M, et al. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone. J Exp Clin Cancer Res 2004;23:47-52.
78. Cheson BD, Bennett JM, Kantarjian H, et al. World Health Organization (WHO international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-3674.
79. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 1998;83:358-368.
80. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 2003;4:P3.
81. Livak KJ. 1997 ABI Prism 7700 Sequence Detection System, User Bulletin #2, Applied Biosystems.
82. Marchetti A, Pellegrini C, Buttitta F, et al. Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation. Lab Investig 2002;82: 729-736.